SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Drenkard C, Villa AR, García-Padilla C, Pérez-Vázquez ME, Alarcón-Segovia D. Remission of systemic lupus erythematosus. Medicine (Baltimore) 1996; 75: 8898.
  • 2
    Chan TM, Li KF, Tang CSO, Wong RWS, Fang GX, Ji YL, et al. Efficacy of Mycophenolate Mofetil in patients with diffuse proliferative lupus nephritis. New Engl J Med 2000; 343: 115662.
  • 3
    Illei GG, Austin HA, Crane M, Collins L, Gourley MF, Yarboro CH, et al. Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Ann Intern Med 2001; 135: 24857.
  • 4
    Llorente L, Richaud-Patin Y, García-Padilla C, Claret E, Jakez-Ocampo J, Cardiel MH, et al. Clinical and biologic effects of anti-interleukin-10 monoclonal antibody administration in systemic lupus erythematosus. Arthritis Rheum 2000; 43: 1790800.
  • 5
    Davis JC Jr, Totoritis JC, Rosenberg J, Sklenar TA, Wofsy D. Phase I clinical trial of a monoclonal antibody against CD40-ligand (IDEC-131) in patients with systemic lupus erythematosus. J Rheumatol 2001; 28: 95101.
  • 6
    Furie RA, Cash JM, Cronin ME, Katz RS, Weisman MH, Aranow C, et al. Treatment of systemic lupus erythematosus with LJP 394. J Rheumatol 2001; 28: 25765.
  • 7
    Alarcón-Segovia D. The future of treatment for systemic lupus erythematosus. Isr Med Assoc J 2001; 3: 12730.
  • 8
    Alarcón-Segovia D, Alcocer-Varela J, Díaz-Jouanen E. The connective tissue diseases as disorders of immune regulation. Clin Rheum Dis 1985; 11: 45169.
  • 9
    Kalunian KC, Davis J, Merril JT, Petri M, Buyon J, Ginzler E, et al. Treatment of systemic lupus erythematosus by inhibition of T cell costimulation [abstract]. Arthritis Rheum 2000; 43 Suppl 9: S271.
  • 10
    Davidson A, Budhai L, Reddy B, Vaishnaw A, Furie R. The effect of anti-CD40L antibody on B cells in human SLE [abstract]. Arthritis Rheum 2000; 43 Suppl 9: S271.
  • 11
    Kalechman Y, Gafter U, Ping D, Albeck M, Alarcón-Segovia D, Sredni B. Delay in the onset of systemic lupus erythematosus following treatment with the immunomodulator AS101. J Immunol 1997; 159: 265867.
  • 12
    Ofosu-Appiah W, Sfeir G, Viti D, Burashnikova E. Suppression of systemic lupus erythematosus disease in mice by oral administration of kidney extract. J Autoimmun 1999; 13: 40514.
  • 13
    McNeeley PA, Iverson GM, Furie RA, Cash JM, Cronin ME, Katz RS, et al. Pre-treatment affinity for LJP 394 influences pharmacodynamic response in lupus patients. Lupus 2001; 10: 52632.
  • 14
    Alarcón-Segovia D, Tumlin J, Furie R, McKay J, Cardiel M, Linnik M, et al. SLE trial shows fewer renal flares in LJP 394-treated patients with high-affinity antibodies to LJP 394: 90-05 trial results [abstract]. Arthritis Rheum 2000; 43 Suppl 9: S272.